Introduction
============

Psoriasis is a chronic immune-mediated inflammatory disease which primarily affects the skin and joints (psoriatic arthritis \[PsA\]), and has been related to metabolic syndrome and some manifestations of cardiovascular disease. Additionally, other comorbidities including Crohn's disease, autoimmune disease, liver disease, malignancy, chronic obstructive pulmonary disease, sleep apnea, uveitis, and depression are associated with psoriasis.[@b1-ccid-9-443],[@b2-ccid-9-443] As such, psoriasis is generally considered as a systemic inflammatory disease.

There are many studies measuring different serum cytokines and growth factors in psoriasis -- some of them correlating with disease severity, such as tumor necrosis factor (TNF)-α, interferon-γ, interleukin (IL)-12, IL-17A, and IL-18.[@b3-ccid-9-443],[@b4-ccid-9-443] Many of these studies were looking for biomarkers of disease -- for example, TNF-α, IL-6, IL-8, IL-17A, soluble TNF receptors-1, and lipocalin 2.[@b5-ccid-9-443],[@b6-ccid-9-443] Meziane et al reported that abdominal obesity and dyslipidemia were metabolic factors significantly related to psoriasis, and hypertension, diabetes, increased levels of triglycerides, and high-density lipoprotein cholesterol were associated with the severity of psoriasis in Moroccan patients with psoriasis.[@b7-ccid-9-443] However, so far there has been no specific research into detailed systemic abnormalities in psoriatic patients. Herein, we conducted a 6-year retrospective study focusing on the patients of first-time hospitalization with psoriasis.

Patients and methods
====================

Ethics statement
----------------

This retrospective study was approved by Institutional Review Board of First Affiliated Hospital of Nanjing Medical University. Written informed consent was obtained from all patients, and the patient records were anonymized and de-identified prior to analysis.

Study population
----------------

Psoriatic inpatient data were collected in the Department of Dermatology of The First Affiliated Hospital of Nanjing Medical University in China from July 2009 to September 2015. The inclusion criteria were first-time hospitalization and without administration of systemic drug therapy (including systemic immunosuppressant, retinoic acid, and biologics or specific antibiotics) or exposure to phototherapy for psoriasis for at least 1 month (biologics should not have been given for at least 3 months).

Detailed systemic indices were evaluated including blood routine examination (BRE), urine examination (UE), blood biochemical examination (BBE, including liver function, renal function, serum lipids, and fasting blood glucose, etc), serum electrolyte analysis (SEA), chest X-ray (CXR), electrocardiogram (ECG), and abdominal ultrasonography (USG). Psoriatic patients were compared with non-psoriasis control subjects whom were randomly selected from the medical examination center in the same hospital.

Statistics
----------

Abnormality rates of each group were calculated and statistical significance was calculated using chi-square test. All absolute counts are presented as mean ± standard deviation, and statistical significance calculated using a two-tailed Student's *t*-test with subsequent Bonferroni correction, or Mann--Whitney *U* test, as appropriate. Significance was defined as *P*≤0.05.

Results
=======

From July 2009 to September 2015, 203 psoriatic inpatients were admitted to the Department of Dermatology of The First Affiliated Hospital of Nanjing Medical University, with 43 cases meeting the inclusion criteria including: 22 moderate-to-severe psoriasis vulgaris (PV) (\[Psoriasis Area Severity Index\] PASI \>10), 15 erythrodermic psoriasis (EP), three generalized pustular psoriasis, and three PsA.

Seven of the 43 patients were female and all patients were \>18 years old with an average age of 50 years. Eight of the 43 patients did not receive systemic treatment for psoriasis for 1 month, and the other 35 patients were not given systemic treatment within 3 months. The disease course of psoriatic patients was from 10 days to 50 years. The number of psoriatic patients with winter flares was 23, and non-winter flares was 17. We randomly chose 44 non-psoriasis control subjects from the medical examination center with a matching age and sex ratio. Any value that was not within the defined normal value range was defined as an "abnormality".

The comparison of detailed systemic abnormalities between psoriatic patients and non-psoriasis controls can be seen in [Table 1](#t1-ccid-9-443){ref-type="table"} and [Figure 1](#f1-ccid-9-443){ref-type="fig"}, which show that the abnormality rates of BRE, UE, BBE, and CXR of psoriatic patients were significantly higher than those of non-psoriasis controls. (*P*\<0.001, *P*=0.021, *P*\<0.001, and *P*\<0.001, respectively). In BRE, the incidence rates of leukocytosis, neutrophilia, hypolymphemia, and erythropenia (or hypochromasia) of psoriasis were significantly higher in comparison with controls (*P*=0.017, *P*\<0.001, *P*\<0.001, and *P*=0.032, respectively). In UE, psoriatic patients had significantly higher incidence rate of leukocytosis compared with controls (*P*=0.003). In BBE, the incidence rates of hypoalbuminemia, abnormal bilirubin, hyperalphalipoproteinemia, and high-density lipoprotein decrease in controls were all significantly lower than those of psoriatic patients (*P*\<0.001, *P*=0.032, *P*=0.004, and *P*=0.003, respectively). Psoriatic patients had common serum electrolyte disturbances (46.51%), especially hypocalcemia (27.91%).

[Table 2](#t2-ccid-9-443){ref-type="table"} and [Figure 2A](#f2-ccid-9-443){ref-type="fig"} show that PV had high incidence rates of abnormal BRE (59.09%), BBE (95.45%), and CXR (63.16%). The corresponding values of EP were 93.33%, 93.33%, and 71.43%, respectively, and EP also had a high incidence rate of serum electrolyte disturbances (73.33%). Compared with PV, EP had significantly higher abnormality rates of BRE and SEA (*P*=0.028 and *P*=0.045, respectively).

We also compared psoriasis with winter flares with non-winter flares. [Table 3](#t3-ccid-9-443){ref-type="table"} and [Figure 2B](#f2-ccid-9-443){ref-type="fig"} show that the abnormality rates of BRE, UE, BBE, SEA, CXR, ECG, and abdominal USG of psoriasis with winter flares had no significant difference compared with those of non-winter flares (*P*\>0.05).

[Figure 3](#f3-ccid-9-443){ref-type="fig"} shows the scatter plots of absolute values of blood leukocytes, lymphocytes, neutrophils, fasting blood glucose, and serum calcium. [Figure 3A](#f3-ccid-9-443){ref-type="fig"} shows the comparison between psoriasis and non-psoriasis controls; the former had significantly higher absolute values for leukocytes and neutrophils (*P*=0.001 and *P*\<0.001, respectively), and significantly lower values for lymphocytes (*P*\<0.001). Fasting blood glucose levels of psoriasis patients were not significantly different to those of controls (*Z*=−0.658, *P*=0.511). [Figure 3B](#f3-ccid-9-443){ref-type="fig"} shows EP had significantly higher absolute values of blood leukocytes, neutrophils, and lower serum calcium compared with those of PV (*P*=0.01, *P*=0.022, and *P*=0.03, respectively). EP and PV had no significant differences in absolute values for blood lymphocytes (*P*=0.502) and blood glucose (*Z*=−0.557, *P*=0.578). The neutrophil-to-lymphocyte ratio (NLR) in the controls was significantly lower than that of psoriatic patients (*P*\<0.001), and NLR of EP was significantly higher in comparison with PV (*P*=0.033).

Discussion
==========

Growing evidence from the last 10 years suggests that several systemic conditions like metabolic syndrome, cardiovascular disease, diabetes, psychological disorders, or inflammatory bowel disease are prevalent in psoriatic patients, and the link might be the chronic secretion of pro-inflammatory cytokines by immune cells and skin.[@b8-ccid-9-443] Drug adverse reaction was deemed to be the cause of abnormalities in BRE and BBE of psoriatic patients in most cases. In this study, we eliminated the possible influence of systemic medications on psoriatic inpatients to evaluate the systemic abnormalities of psoriasis objectively and accurately. In our study, the most common comorbidity was metabolic disorder, according to examination results.

The psoriatic patients commonly had elevated peripheral blood leukocytes and neutrophils, which was shown in our study, and it also showed EP had higher absolute counts of leukocytes and neutrophils than that of moderate-to-severe PV. NLR has been used as a marker for systemic inflammation status, and was considered to be a measure of systemic inflammation in psoriasis.[@b9-ccid-9-443],[@b10-ccid-9-443] NLR was also deemed to be potentially a predictor of subclinical atherosclerosis in patients with psoriasis.[@b11-ccid-9-443] Our study showed that psoriasis had higher NLR compared with non-psoriasis controls, and EP had higher NLR in comparison with PV, in parallel, EP had higher disease severity (PASI) scores, indicating that EP had more intense systemic inflammation.

Anemia is not a commonly-reported comorbidity of psoriasis. However, our study found psoriatic patients had a higher incidence rate of peripheral blood erythropenia or hypochromasia compared with non-psoriasis controls. Harada et al reported long-term adalimumab treatment might cause autoimmune hemolytic anemia which resolved after replacing the adalimumab treatment with prednisolone therapy.[@b12-ccid-9-443] Drug side-effects might be a possible reason for erythropenia or hypochromasia of psoriasis, although we tried to lessen drug interference in our study design, nevertheless, we should take note of the possible abnormality in peripheral blood erythrocytes and hemoglobin of psoriatic patients.

Clinicians seldom pay attention to the urine of psoriatic patients, except to the presence of urine protein. Urinary proteome analysis could identify potentially predictive biomarkers for methotrexate-induced hepatic fibrosis in psoriasis with high cumulative dose of methotrexate.[@b13-ccid-9-443] Interestingly, our study found psoriasis had more abnormalities in UE in comparison with non-psoriasis controls, and the main manifestation was urine leukocytosis, which suggested that psoriatic patients were prone to urinary infections, particularly as psoriatic patients treated with immunosuppressants or biological agents such as anti-TNF-α agents are at an increased risk of infections.

In BBE, 40 of 43 psoriatic patients had abnormalities including hypoalbuminemia, abnormal bilirubin, hyperalphalipoproteinemia, and high-density lipoprotein decrease, which were related to metabolic disturbance and had significantly higher incidence rates than non-psoriasis controls. Psoriasis has been reported to be associated with raised serum uric acid levels and increased risk of developing type 2 diabetes.[@b14-ccid-9-443],[@b15-ccid-9-443] However, in our study the incidence rate of hyperuricaemia and hyperglycemia was not significantly different between psoriasis patients and controls, which might be due to the small sample size. Fasting blood glucose levels of PV also had no marked difference in comparison with EP. Interestingly, moderate-to-severe PV and EP both had high abnormality rates in BBE but there were no significant differences, which indicated that moderate-to-severe PV might have similar severe systemic inflammation to EP.

Almost half (46.51%) of psoriatic patients had serum electrolyte disturbances, and the main manifestation was hypocalcemia. Hypocalcemia is a risk factor for psoriasis.[@b16-ccid-9-443] A recent study reported that serum calcium levels could predict the efficacy of methotrexate in the treatment of severe plaque psoriasis, and better improvements were observed in psoriatic patients with higher serum calcium.[@b17-ccid-9-443] In our study, comparing moderate-to-severe PV with EP, the latter had higher disease severity (PASI) scores but significantly lower serum calcium levels, which may be a useful predictor of EP treatment outcomes.

Abnormal CXR signs could be seen in 64.1% of psoriatic patients which was mainly expressed in increased lung markings, whereas the abnormality rate of CXR in non-psoriasis controls was 9.09%. Psoriatic patients were at a greater risk of developing chronic obstructive pulmonary disease than the general population and that the association between of psoriasis and with chronic obstructive pulmonary disease was stronger among patients with severe psoriasis.[@b18-ccid-9-443] As a mark of early lung injury, increase of lung markings should be paid close attention to.

Our study found the main abnormality of ECG in psoriatic patients was sinus irregularity, which had no significant difference compared with non-psoriasis controls. However, a recent study with a large sample size reported that patients with psoriasis were at higher risk of developing arrhythmia, particularly for those with PsA, independent of traditional cardiovascular risk factors.[@b19-ccid-9-443] Trial conduction of sinus impulses was impaired in patients with PV, which was more prominent in patients with severe disease, and physicians caring for patients with PV should screen them for atrial fibrillation development.[@b20-ccid-9-443] In our study, USG abnormality in psoriatic patients was mainly fatty liver; however, the incidence rate also had no marked difference compared with the controls. However, in another study, Gisondi et al reported that prevalence of nonalcoholic fatty liver disease was greater in patients with psoriasis than in controls, and fibrosis score of nonalcoholic fatty liver disease was also higher in psoriasis, suggesting a higher risk of liver fibrosis in those with psoriasis.[@b21-ccid-9-443]

The majority of psoriatic patients grow worse in the cold winter but improve in the summer months, whereas other patients have no such distinguishing features or illness is aggravated in summer.[@b22-ccid-9-443] Various examinations in psoriasis with winter flares seemed to have no significant difference in comparison with those of non-winter flares; however, we considered differences might appear with a sample size increase.

Limitations
===========

The major limitations of this study are its retrospective and inpatient nature. Patients who are admitted are different from patients who are seen in the outpatient setting: inpatients generally have a much more severe illness than outpatients. Another limitation is that this was a single center research. However, fortunately, the electronic data of patients and non-psoriasis controls were quite comprehensive and comparable; moreover, our rigorous inclusion criteria rendered this study a dependable result.

Conclusion
==========

To our knowledge, our study is the first report in relation to the detailed assessment about systemic abnormalities of psoriatic patients prior to systemic treatment. The systemic condition of psoriatic patients should be observed by clinicians before systemic therapy, and systemic abnormalities of different types of psoriasis should be taken care of during patient care.
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###### 

The comparison of detailed systemic abnormalities between psoriatic patients and non-psoriasis controls

  Abnormality                         Psoriasis (n=43)   Controls (n=44)   *χ*^2^ values   *P*-values
  ----------------------------------- ------------------ ----------------- --------------- ------------
  **Blood routine examination**       32 (74.42)         12 (27.27)        19.338          \<0.001
  Leukocytosis                        11 (25.58)         3 (6.81)          5.67            0.017
  Neutrophilia                        15 (34.88)         1 (2.27)          15.41           \<0.001
  Eosinophilia                        7 (16.28)          1 (2.27)          3.57            0.059
  Hypolymphemia                       17 (39.53)         1 (2.27)          18.402          \<0.001
  Monocytosis                         7 (16.28)          3 (6.81)          1.096           0.295
  Erythropenia or hypochromasia       8 (18.6)           1 (2.27)          4.617           0.032
  Thrombocytosis                      8 (18.6)           2 (4.55)          2.956           0.086
  Thrombocytopenia                    3 (6.98)           0 (0)             1.429           0.232
  **Urine examination**               15 (34.88)         6 (13.64)         5.362           0.021
  Leukocytosis                        10 (23.26)         1 (2.27)          8.669           0.003
  Erythremia                          4 (9.3)            3 (6.82)          0.001           0.975
  Urine protein                       6 (13.95)          4 (9.09)          0.14            0.708
  Hyperglycosuria                     5 (11.63)          1 (2.27)          1.686           0.194
  **Blood biochemical examination**   40 (93.02)         18 (40.91)        26.578          \<0.001
  Hepatic dysfunction                 11 (25.58)         6 (13.64)         1.974           0.16
  Renal dysfunction                   2 (4.65)           0 (0)             N/A             0.241
  Hyperuricaemia                      7 (16.28)          3 (6.82)          1.096           0.295
  Hyperglycemia                       7 (16.28)          2 (4.55)          2.087           0.149
  Hypoalbuminemia                     21 (48.84)         1 (2.27)          24.958          \<0.001
  Abnormal bilirubin                  8 (18.6)           1 (2.27)          4.617           0.032
  Hyperalphalipoproteinemia           9 (20.93)          0 (0)             8.139           0.004
  High-density lipoprotein decrease   23 (53.49)         10 (22.73)        8.741           0.003
  **Serum electrolyte analysis**      20 (46.51)         N/A               N/A             N/A
  Hypokalemia                         5 (11.63)          N/A               N/A             N/A
  Hypocalcemia                        12 (27.91)         N/A               N/A             N/A
  Hyposodemia                         1 (2.34)           N/A               N/A             N/A
  Hypophosphatemia                    2 (4.65)           N/A               N/A             N/A
  **Chest X-ray**                     25 (64.1, n=39)    4 (9.09)          27.524          \<0.001
  **Electrocardiogram**               15 (39.47, n=38)   13 (29.55)        0.894           0.344
  **Abdominal ultrasonography**       18 (62.07, n=29)   26 (59.09)        0.065           0.799

**Note:** Data presented as n (%).

**Abbreviation:** N/A, not applicable.

###### 

The systemic abnormalities of PV, EP, GPP, and PsA

  Abnormality                     PV (n=22)          EP (n=15)          *X*^2^ values   *P*-values   GPP (n=3)   PsA (n=3)
  ------------------------------- ------------------ ------------------ --------------- ------------ ----------- -----------
  Blood routine examination       13 (59.09)         14 (93.33)         N/A             0.028        3 (100)     2 (66.67)
  Urine examination               6 (27.27)          5 (33.33)          N/A             0.728        3 (100)     1 (33.33)
  Blood biochemical examination   21 (95.45)         14 (93.33)         N/A             1            3 (100)     2 (66.67)
  Serum electrolyte analysis      8 (36.36)          11 (73.33)         N/A             0.045        0 (0)       1 (33.33)
  Chest X-ray                     12 (63.16, n=19)   10 (71.43, n=14)   N/A             0.719        2 (66.67)   1 (33.33)
  Electrocardiogram               8 (42.11, n=19)    5 (38.46, n=13)    N/A             1            1 (33.33)   1 (33.33)
  Abdominal ultrasonography       11 (64.71, n=17)   4 (57.14, n=7)     N/A             1            1 (33.33)   2 (66.67)

**Note:** Data presented as n (%).

**Abbreviations:** PV, psoriasis vulgaris; EP, erythrodermic psoriasis; GPP, generalized pustular psoriasis; PsA, psoriatic arthritis; N/A, not applicable.

###### 

The comparison of systemic abnormalities between psoriasis with winter flares and non-winter flares

  Abnormality                     Winter flares (n=23)   Non-winter flares (n=17)   *X*^2^ values   *P*-values
  ------------------------------- ---------------------- -------------------------- --------------- ------------
  Blood routine examination       18 (78.26)             11 (64.71)                 0.349           0.555
  Urine examination               8 (34.78)              6 (35.29)                  0.001           0.973
  Blood biochemical examination   22 (95.65)             15 (88.24)                 0.075           0.785
  Serum electrolyte analysis      11 (47.83)             9 (52.94)                  0.102           0.749
  Chest X-ray                     14 (63.64, n=22)       9 (64.29, n=14)            N/A             1
  Electrocardiogram               9 (47.37, n=19)        5 (33.33, n=15)            N/A             0.495
  Abdominal ultrasonography       9 (60, n=15)           9 (75, n=12)               N/A             0.683

**Note:** Data presented as n (%).

**Abbreviation:** N/A, not applicable.
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